we want to make sure that when a patient gets a pfizer medication, that they get a pfizer medication. not some knock off. >> reporter: some of what they are finding online is frightening. >> they will use things like brick dust to hold it together. they will use wallboard, sheet rock to hold these things together because they compress well. >> reporter: to see if the facilitators are different from the online sellers, pfizer agreed to help us put them to the test. we ordered brand-new lipator and filled four more at pharmacies in new york and new jersey. i need to get this prescription filled. i need the brand name. >> reporter: the first difference is obvious, the price. the facilitators charged us on average $1.71 per pill. the pharmacies more than four times that. >> $182.74. >> reporter: when we got our shipments, there was another difference. the pills from the pharmacies are oblong but look at the pills from facilitators, they are round. we sent simples of each to pfizer's lab. think you know how the test came back? think again. according to pfizer's report, the oblong lipator c

we want to make sure that when a patient gets a pfizer medication, that they get a pfizer medicationome knockoff. >> reporter: some of what they're finding online is frightening. >> they'll use things like brick dust to hold it together. they'll use wall board, sheetrock to hold it -- to hold these things together because they compress well. >> reporter: to see if the facilitators are any different from the online sellers, pfizer agreed to help put us to the test. we ordered brand name lipitor and we filled two more prescriptions in new york and new jersey at traditional pharmacies. >> i need to get the prescription filled. i need the brand name. >> the first difference is obvious. the price. the facilitators charged us $1.71 per pill. the pharmacies, more than four times of that. >> $182.74 when we got our prescriptions, the difference was noticeable. we sent samples to pfizer's lab removing packaging to keep the tests blind. do you think you know how the tests came back? think again. according to pfizer's own reports, the oblong lipitor came back authentic. no surprise. but what ab

when want to make sure when a patient gets a pfizer medication, they get a pfizer medication, not someoff. >> that is brian donnelly, he's a pharmacist and undercover agent. he says what is produced by the counterfeiters is downright scary. >> they will use things like brick dust to hold it together. they'll use wallboard, sheet rock, to hold these things together because they compress well. then, of course, they may use different things to color these things, printer ink, for example. to color it. >> now, storefronts like these are popping up, they will place an order for you. they say they are operating legally and big pharma is trying to scare you. so we went under cover to put these places to the test t. result of that test surprised us. we will have it later for you today on power lunch. like everything else, this is not as simple as it may seem. >> surprised you in a bad way, though? >> it took an interesting twist, put it that way. basically, we went under cover to a number of these facilitators, got some product, had it tested and went with some assumptions that were not necess

companies, one major medical ceo denied to maria bartiromo that his company is considering such a strategy. >> i want to talk about this trend going on, tax inversion. you have pfizer acquire astrazeneca you have a couple of medical device companies getting together. moving their headquarters out of the u.s. would that be something j&j would consider? >> no. is the short answer, maria. >> there are other u.s. executives shunning inversion wave. mark cuban, for example, tweets, quote, if i owned stock in your company, and you move offshore for tax reasons, i am selling your stock. there are enough investment choices here. this while a former obama administration treasury official has suggested the administration could reduce inversion deals through regulation without a law change from congress. treasury secretary jack lew says the administration has no such authority and says congress must act. democrats are making republican opposition to their inversion proposals a significant part of their midterm election campaign. back to you. ashley: thank you, rich. fighting words from mark cuban for sure but there are companies that have shareholders, look we need best retur

records under section 216 of the patriot act and its monitoring of internet to medications under section 702 of the pfizer amendments act. threatening to the basic security of the internet. encryptiondermining tools and standards, inserting backdoors into widely used software products, commercial software we use every day vulnerabilities, rather than making sure these get fixed, building a vast network of spyware inserted into computers and routers around the world, including by impersonating popular sites like facebook and linkedin, and even hacking into google's private data links. finally, congress is starting to pay attention to how the nsa threatening not just our privacy, but cyber security itself. the house, overwhelmingly voted to approve two amendments to the defense appropriations bill that would defund the nsa's attempt to undermine decryption standards and insert backdoors for surveillance into the to medications technologies we rely on. alan were sponsored by grayson and backed by a broad coalition. today, after it brief prerecorded introductions by both lawmakers, who were today flying back

including eitems of pfizer saying they are earning 58 cents more a share because of the oncology drugs, and merck saying that they have offset with patent protection on older medications. nasonex came off, and some of the 2.4 billion of the consumer care business to buyer, and neither of which are closed so they are still in process. >> yes, missed a lot of cash there and this is finally the monetizing of the shooting plow of what some people thought was a high price. but they have a lot of levers, merck, to be able to make it so that people say, you know what, i just might stay long on this great american blue chip. >> and great sales for the big five franchises up 6% and they say that the fda could make a decision on the cancer immunotherapy by october. that is another catalyst. >> yes, we thought that pfizer would do the inversion, and merck has flexibility to do animal health which is a great, great business and franchise they have. these companies have a lot hidden asset, and all of this is happening within the same confines over and over again. companies are looking at what they have and say issing this is worth more to someone else, and this makes our company m

medical device company, is making a deal to leave. walgreens, which has stores everywhere? they are in the middle of trying to do a deal to leave. pfizertried to leave, but that deal blew up for a variety of technical reasons. to allanare speaking sloan about his cover story, companies moving overseas to dodge billions in taxes. we want to get to your questions. mr. sloan, it looks like your story, which also appeared in the washington post on sunday, is getting some traction. the president is urging action to limit these inversions. the obama administration reportedly joined the growing debate over u.s. companies reincorporating overseas, urging lawmakers to pass legislation to limit the moves. what can congress do? >> congress can do two things. they could do something quickly and simply. sander levin was in the house, carl levin was in the senate. that changed some of the technicalities and made it hard to invert right now. the right thing, the united states tax code, it is more attractive for companies to stay here right now and less attractive for them to leave. i doubt they will actually do this. some way to throw a harpoon into